




510(k) SUMMARY Prevena Incision Management System with Customizable Dressing

OCT 1 1 2012

·····	With Oustonie D	10001119		
Submitter Information [21 CFR 807.929(a)(1)]				
Name	KCI USA, Inc. (Kinetic Concepts, Inc.)			
Address	6203 Farinon Drive			
	San Antonio, TX 78249			
Phone number	210-515-4368			
Fax number	210-255-6727			
Establishment Registration Number	1625774			
Name of contact person.	Shannon Scott, Regulatory Affairs Senior Manager			
Date prepared	June 26, 2012			
Name of the device [21	CFR 807.92(a)(2)]			
Trade or proprietary name	Prevena Incision Management System with Customizable Dressing			
Common or usual name	Negative Pressure Wound Therapy System			
Classification name	Negative Pressure Wound Therapy Powered Suction Pump (and components)			
Classification panel	General and Plastic Surgery			
Regulation	878.4780			
Product Code(s)	OMP			
Legally marketed device(s) to which equivalence is claimed [21 CFR 807.92(a)(3)]	Prevena Incision Management Sys	tem (K100821)		
Device description [21 CFR 807.92(a)(4)]	Negative pressure wound therapy system for application to surgically closed incisions.			
Indications for use [21 CFR 807.92(a)(5)]	The Prevena Incision Management System is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy.			
Summary of the technolo [21 CFR 807.92(a)(6)]	gical characteristics of the device	compared to the predicate device		
The subject device was for the indicated wound type.	ind to be equivalent to the predicate The devices are equivalent in terms	device in delivery of negative pressure to of functional components.		
Characteristic	New Device Prevena [™] Incision Management System with Customizable Dressing	Predicate Prevena [™] Incision Management System with Peel and Place Dressing K100821		
Indicated wound types	Same as predicate	Closed surgical incisions		
Dressing	Multiple dressing components	Single, one size, multi-layer dressing.		
·	L	<u> </u>		





Therapy unit Same as predicate Single patient use only; battery powered

Performance Data [21 CFR 807.92(b)]

Summary of non-clinical tests conducted for determination of substantial equivalence [21 CFR 807.92(b)(1)]

The Prevena Incision Management System with Customizable Dressing was evaluated under a number of design verification and validation tests to assure safety, efficacy, conformance to design specifications and equivalence to the predicate device. The following tests were conducted:

- Biocompatibility testing according to ISO 10993-1
- Equivalency testing of the Prevena Customizable Dressing to the Prevena Peel and Place Dressing with respect to delivery of negative pressure wound therapy
- · Software verification and validation testing

Summary of clinical tests conducted for determination of substantial equivalence or of clinical information [21 CFR 807.92(b)(2)]

Clinical tests were conducted to demonstrate substantial equivalence with regard to device performance.

Conclusions drawn [21 CFR 807.92(b)(3)]

Testing demonstrates that the Prevena Incision Management System with Customizable Dressing and the Prevena Incision Management System with Peel and Place Dressing are substantially equivalent in terms of both indications for use and delivered wound therapy.







Food and Drug Administration 10903 New Hampshire Avenue Document Control Room --WO66-G609 Silver Spring, MD 20993-0002

OCT 1 1 2012

Kinetic Concepts USA, Incorporated % Ms. Shannon Scott Regulatory Affairs Senior Manager 6203 Farinon Drive San Antonio, Texas 78249

Re: K121883

Trade/Device Name: Prevena Incision Management System

Regulation Number: 21 CFR 878.4780 Regulation Name: Powered suction pump

Regulatory Class: Class II Product Code: OMP Dated: September 7, 2012

Received: September 10, 2012

Dear Ms. Scott:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21)

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

Device Name:Prevena Incision Indications for Use:		·	
The Prevena Incision Management surgical incisions that continue to dr maintaining a closed environment a pressure wound therapy.	rain following sutured or	stapled closure by	
		•	
		,	

•			
		. •	·
a de la companya de l			
Prescription UseX (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELO)	AND/OR (21 CFR	e-Counter Use R 801 Subpart C) E ON ANOTHER PA	.GE OF
Concurrence of CDF	RH, Office of Device Eva	luation (ODE)	
(Posted November 13, 2003)	(Division Sign-Off) Division of Surgical, and Restorative Dev	ices	_of_1 311
	510(k) Number	141883	